×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ZOM – zomedica corp. common shares (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ZOM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/14
06:52 am
zom
Zomedica Launches Quantitative Insulin Assay for Equine Plasma on the TRUFORMA(R) Platform [Yahoo! Finance]
Medium
Report
Zomedica Launches Quantitative Insulin Assay for Equine Plasma on the TRUFORMA(R) Platform [Yahoo! Finance]
11/14
06:30 am
zom
Zomedica Launches Quantitative Insulin Assay for Equine Plasma on the TRUFORMA(R) Platform
Medium
Report
Zomedica Launches Quantitative Insulin Assay for Equine Plasma on the TRUFORMA(R) Platform
11/12
08:30 am
zom
Sidoti Events, LLC's Virtual November Micro-Cap Conference
High
Report
Sidoti Events, LLC's Virtual November Micro-Cap Conference
11/12
06:30 am
zom
Noble Capital Markets Initiates Equity Research Coverage on Zomedica
High
Report
Noble Capital Markets Initiates Equity Research Coverage on Zomedica
11/8
02:18 pm
zom
Zomedica Corp (ZOM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ... [Yahoo! Finance]
Neutral
Report
Zomedica Corp (ZOM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ... [Yahoo! Finance]
11/8
06:30 am
zom
Zomedica to Present at the Sidoti Micro Cap Conference November 14, 2024
Low
Report
Zomedica to Present at the Sidoti Micro Cap Conference November 14, 2024
11/7
04:25 pm
zom
Zomedica Announces Third Quarter 2024 Financial Results: Revenue Up 10% to $7 Million; 72% Gross Margin, and $78 Million in Liquidity to Support Growth
Medium
Report
Zomedica Announces Third Quarter 2024 Financial Results: Revenue Up 10% to $7 Million; 72% Gross Margin, and $78 Million in Liquidity to Support Growth
10/24
06:30 am
zom
Zomedica Launches Ear Cytology Quick Scan Protocol for TRUVIEW(TM) Digital Microscope & Telepathology Platform
Low
Report
Zomedica Launches Ear Cytology Quick Scan Protocol for TRUVIEW(TM) Digital Microscope & Telepathology Platform
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/19
05:04 pm
zom
Form 8-K Zomedica Corp. For: Nov 15
Low
Report
Form 8-K Zomedica Corp. For: Nov 15
11/13
04:16 pm
zom
Form 4 Zomedica Corp. For: Nov 11 Filed by: POWERS JOHNNY D
Medium
Report
Form 4 Zomedica Corp. For: Nov 11 Filed by: POWERS JOHNNY D
11/13
04:15 pm
zom
Form 4 Zomedica Corp. For: Nov 11 Filed by: Whelan Sean
Medium
Report
Form 4 Zomedica Corp. For: Nov 11 Filed by: Whelan Sean
11/13
04:14 pm
zom
Form 4 Zomedica Corp. For: Nov 11 Filed by: Rowe Jeffrey M
Medium
Report
Form 4 Zomedica Corp. For: Nov 11 Filed by: Rowe Jeffrey M
11/13
04:13 pm
zom
Form 4 Zomedica Corp. For: Nov 11 Filed by: POWERS JOHNNY D
Medium
Report
Form 4 Zomedica Corp. For: Nov 11 Filed by: POWERS JOHNNY D
11/13
04:12 pm
zom
Form 4 Zomedica Corp. For: Nov 11 Filed by: Nichols Pamela
Medium
Report
Form 4 Zomedica Corp. For: Nov 11 Filed by: Nichols Pamela
11/13
04:11 pm
zom
Form 4 Zomedica Corp. For: Nov 11 Filed by: MACLEOD CHRISTOPHER ROSS
Medium
Report
Form 4 Zomedica Corp. For: Nov 11 Filed by: MACLEOD CHRISTOPHER ROSS
11/13
04:10 pm
zom
Form 4 Zomedica Corp. For: Nov 11 Filed by: Cohen Robert
Medium
Report
Form 4 Zomedica Corp. For: Nov 11 Filed by: Cohen Robert
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/8
Zomedica Pharma down 38% premarket after pricing stock offering [Seeking Alpha]
34.1%
2/26 Zomedica Pharmaceuticals Corp. Announces Year End 2019 Financial Results 24.3%
9/11 Zomedica to Present at the Fall Investor Summit on Monday, September 16 in New York City 15.6%
5/20 Form 8-K Zomedica Pharmaceuticals For: May 20 13.0%
8/19 Form 3 Zomedica Pharmaceuticals For: Aug 16 Filed by: POWERS JOHNNY D 9.8%
2/11 Zomedica Files U.S. Patent Application for Fecal Parasite Detection 8.9%
5/10 Zomedica Announces Private Placement of Preferred Shares 8.5%
2/14 Zomedica Announces Completion of $2.5 Million Registered Direct Offering 8.4%
11/3 Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE: ZOM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 8.1%
6/10 Zomedica Announces $7 Million Second Tranche Closing of Preferred Shares 6.6%
2/26 Zomedica Pharmaceuticals Corp. Announces Year End 2019 Financial Results 24.3%
9/11 Zomedica to Present at the Fall Investor Summit on Monday, September 16 in New York City 15.6%
5/20 Form 8-K Zomedica Pharmaceuticals For: May 20 13.0%
8/19 Form 3 Zomedica Pharmaceuticals For: Aug 16 Filed by: POWERS JOHNNY D 9.8%
2/11 Zomedica Files U.S. Patent Application for Fecal Parasite Detection 8.9%
5/10 Zomedica Announces Private Placement of Preferred Shares 8.5%
2/14 Zomedica Announces Completion of $2.5 Million Registered Direct Offering 8.4%
11/3 Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE: ZOM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 8.1%
6/10 Zomedica Announces $7 Million Second Tranche Closing of Preferred Shares 6.6%
TOP News Decliners
2/12
Zomedica Announces $2.5 Million Registered Direct Offering
-38.9%
4/7 Zomedica Pharmaceuticals Corp. Announces Public Offering -20.1%
6/13 Zomedica Announces Completion of Initial Development of a Lymphoma Assay for its Canine Cancer Liquid Biopsy Platform -15.6%
2/21 Form SC 13G Zomedica Pharmaceuticals Filed by: ARMISTICE CAPITAL, LLC -12.2%
5/10 Form 10-Q Zomedica Pharmaceuticals For: Mar 31 -9.1%
3/17 Form 4 Zomedica Pharmaceuticals For: Mar 13 Filed by: Herbst Bruk -8.9%
1/24 Form SC 13D Zomedica Pharmaceuticals Filed by: EQUIDEBT LLC -8.5%
1/22 Form 8-K Zomedica Pharmaceuticals For: Jan 17 -7.7%
2/13 Form 8-K Zomedica Pharmaceuticals For: Feb 12 -6.5%
11/23 Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE: ZOM) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -6.2%
4/7 Zomedica Pharmaceuticals Corp. Announces Public Offering -20.1%
6/13 Zomedica Announces Completion of Initial Development of a Lymphoma Assay for its Canine Cancer Liquid Biopsy Platform -15.6%
2/21 Form SC 13G Zomedica Pharmaceuticals Filed by: ARMISTICE CAPITAL, LLC -12.2%
5/10 Form 10-Q Zomedica Pharmaceuticals For: Mar 31 -9.1%
3/17 Form 4 Zomedica Pharmaceuticals For: Mar 13 Filed by: Herbst Bruk -8.9%
1/24 Form SC 13D Zomedica Pharmaceuticals Filed by: EQUIDEBT LLC -8.5%
1/22 Form 8-K Zomedica Pharmaceuticals For: Jan 17 -7.7%
2/13 Form 8-K Zomedica Pharmaceuticals For: Feb 12 -6.5%
11/23 Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE: ZOM) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -6.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: